A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings) All doses of semaglutide (Ozempic, ...

Ozempic, known generically as semaglutide, is an injectable prescription drug. It was approved in 2017 by the United States ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...